ZOETIS INC. (ZTS) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry...
ZOETIS INC.'s revenue increased 2.3% year over year, from $9.26B to $9.47B.
Net income increased 7.5% over the same period, from $2.49B to $2.67B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 94% in total.
Total debt increased by 73.2% to $9.04B.
The debt-to-equity ratio stands at 2.71, indicating a high leverage profile.
Operating cash flow declined 1.7% to $2.90B.
ZOETIS INC. maintains a strong net profit margin of 28.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $6.33B+51.5% | $1.82B | $4.50B | $2.29B | $1.46B | $14.11B | $6.55B | $5.08B |
| Q1 FY2024 | $2.19B-65.4% | $599.0M | $1.55B | $747.0M | $595.0M | $14.35B | $6.59B | $5.06B |
| Q2 FY2024 | $4.55B+107.8% | $1.22B | $3.24B | $1.53B | $1.10B | $14.16B | $6.56B | $4.97B |
| Q3 FY2024 | $6.94B+52.5% | $1.91B | $4.93B | $2.40B | $2.05B | $14.36B | $6.57B | $5.23B |
| Q1 FY2025 | $2.22B-68.0% | $631.0M | $1.60B | $810.0M | $587.0M | $14.10B | $5.23B | $4.66B |
| Q2 FY2025 | $4.68B+110.8% | $1.35B | $3.41B | $1.71B | $1.07B | $14.48B | $5.23B | $4.98B |
| Q3 FY2025 | $7.08B+51.3% | $2.07B | $5.13B | $2.60B | $2.01B | $15.16B | $7.07B | $5.40B |
| Q1 FY2026 | $2.26B-68.1% | $601.0M | $1.62B | $758.0M | $401.0M | $15.15B | $9.04B | $3.23B |
Balance Sheet Summary (Latest Period)
Total Assets
$15.50B
Total Liabilities
$12.14B
Total Equity
$3.33B
Cash & Equivalents
$2.31B
Total Debt
$9.04B
Current Assets
$6.77B
Current Liabilities
$2.23B
Retained Earnings
$13.74B